SAN DIEGO, Feb. 13 /PRNewswire/ -- The world antibody business development and investment community will be convening in San Diego on April 8-9 to attend, speak, and exhibit at ``Trends in Antibody Deal-Making & Financing,'' announces Strategic Research Institute.
This distinct meeting & one of the first ever in the antibody deal-making arena, will feature presenters from many of the leading biotech and VC backed firms, large and small -- in addressing the components of antibody deal-making such as valuations, deal structures, terms and business strategies. You will engage in massive networking opportunities from conference start to finish.
The conference is organized into 3 main sections: 1) Venture-Backed Antibody & Antibody Mimic Startups, 2) Partnering of Early-Stage Antibody Technologies, & 3) Partnering & Deal-Making: The Bigger Picture.
Participants include: Abgenix, AbTECH S.A., Affitech A.S., Altarex Corporation, Arius Research, AMGEN, Atopix Pharmaceuticals, Bard Biopharma, Bioscience Ventures, Inc., Cambridge Antibody Technology, Castle Creek Life Science Partners, Celltech Group plc, Chiron Corporation, Corixa Corporation, Exelixis Inc., Forward Ventures, Genentech, Genway Biotech, IDEC Pharmaceuticals, Immunogen Inc., J&J Development Venture Corp., Johnson & Johnson, Lexicon Genetics, Medarex, Merck, Protein Design Labs, Raven Biotechnologies, Redington Partners Inc. & Roth Capital.
Two important VC panels will be featured on the first day, entitled, ``Buy-Side & VC Perspective of Antibody Investments'' & ``Wall Street's View on Antibody Financing''. To date 60 individuals have signed up for the meeting.
To request the agenda in PDF format & list of registered companies on Word, please contact Ed Drilon at edrilon@srinstitute.com or 212-967-0095 x233. Include your fax number, affiliation and mailing address. |
